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Background
Poxvirus vectors, particularly the attenuated and host-
range restricted ALVAC, MVA and NYVAC, have been
extensively used to develop the so-called T-cell vaccines.
ALVAC has been a major component of a prime/boost
vaccine regimen currently tested in phase III clinical trial
and MVA and NYVAC have shown good levels of immu-
nogenicity in combination with DNA priming. Despite
the promising immunogenicity data, there is common
agreement that the poxvirus vector T-cell vaccines need to
be improved.
Methods
In order to improve the immunogenicity of NYVAC we
have used two strategies: a) development of attenuated
replication competent (in human cells) NYVAC and b)
deletion of poxvirus genes known to encode for proteins
that may affect the immune response. The newly gener-
ated replication competent or gene deletion NYVAC
mutants expressing env, gag, pol and nef have been evalu-
ated for their ability to stimulate HIV-specific CD8 T-cell
responses from blood mononuclear cells of HIV-infected
subjects. HIV-specific immune responses induced by the
new NYVAC vectors were evaluated in newly developed
direct and cross-presentation assays in vitro and compared
with the parental replication deficient NYVAC vector.
Finally, expression of gag following infection of different
target cells (dendritic cells and HeLa cells) with replica-
tion competent and deficient NYVAC vectors was also
evaluated.
Results
The results obtained indicated that replication competent
NYVAC vectors induce: a) improvement in direct and
cross-presentation, and b) substantial increase in the
expression of gag in the infected target cells.
Conclusion
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